Discovery of DDX41 as A Potential Drug Target and Biomarker (G51428)

Target Name: DDX41

NCBI ID: G51428

DDX41

Discovery of DDX41 as A Potential Drug Target and Biomarker

DDX41 (MGC8828) is a drug target (also known as a potential biomarker) that has been identified using a combination of genetic and biochemical techniques. It is a small non-coding RNA molecule that is expressed in various tissues and cell types, including the brain, heart, and kidneys.

The discovery of DDX41 was made by a research team led by Dr. Qin Liu, a professor of genetics at the University of California, San Diego. The team used a combination of high-throughput sequencing and bioinformatics tools to identify a gene that was highly expressed in the brain and other tissues, but was not found in any known gene databases.

To further study the gene, the team used RNA interference techniques to knockdown the gene in mice, and found that the mice showed reduced learning and memory skills compared to control mice. This suggests that the gene is involved in the function of the brain and may play a role in the development of certain neurological conditions.

The team also used the RNA-seq technology to study the gene expression in various tissues and cell types, and found that the gene was highly expressed in the brain, heart, and kidneys. The team also identified a number of potential interacting genes, including genes involved in the development and progression of cancer.

These findings suggest that DDX41 may be a promising drug target for the treatment of a wide range of conditions, including neurological and psychiatric disorders. The team is currently working to identify potential small molecules that can interact with the gene and are investigating their potential therapeutic benefits.

In addition to its potential therapeutic applications, DDX41 also has potential as a biomarker for the diagnosis and monitoring of various diseases. The team has used the gene to create a diagnostic assay that can detect the expression of the gene in various tissues and cell types, which may be useful for the diagnosis of certain genetic disorders.

Overall, the discovery of DDX41 (MGC8828) as a drug target and biomarker has significant implications for the development of new treatments for a wide range of conditions. Further research is needed to fully understand the function of the gene and its potential therapeutic applications.

Protein Name: DEAD-box Helicase 41

Functions: Probable ATP-dependent RNA helicase. Is required during post-transcriptional gene expression. May be involved in pre-mRNA splicing

The "DDX41 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX41 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets